We have cloned a mouse cDNA homolog of P450RAI, a cytochrome P450 belonging to a new family (CYP26), which has previously been isolated from zebrafish and human cDNAs and found to encode a retinoic acid-inducible retinoic acid hydroxylase activity. The crossspecies conservation of the amino acid sequence is high, particularly between the mouse and the human enzymes, in which it is over 90%. Like its human and zibrafish counterparts, the mouse P450RAI cDNA catalyzes metabolism of retinoic acid into 4-OH-retinoic acid, 4-oxo-retinoic acid, 18-OH-retinoic acid, and unidentified water-soluble metabolites when transfected into COS-1 cells. Retinoic acid-inducible retinoic acid metabolism has previously been observed in F9 murine embryonal carcinoma cells and some derivatives lacking retinoid receptors. We were interested in determining whether P450RAI could be responsible for retinoic acid metabolism in F9 cells and in studying the effect of retinoid receptor ablation on P450RAI expression. In wild-type F9 cells and derivatives lacking RAR␥, RAR␣, and/or RXR␣, we observed a direct relationship between the level of retinoic acid metabolic activity and retinoic acid-induced P450RAI mRNA. These experiments, as well as others using synthetic receptor subtype-specific retinoids, suggest that the RAR␥ and RXR␣ receptors mediate the effects of retinoic acid on the expression of the P450RAI gene.
epithelial tissues (7) . It also has a dramatic effect on growth and differentiation of cells in culture (8, 9) and has been shown to be effective in prevention and treatment of various human cancers, including leukemias (10) , secondary tumors of the head and neck (11) , and cervical cancer (12) . The importance of vitamin A levels in mammals is manifested in conditions of vitamin A depletion or excess. Vitamin A deficiency during embryonic development results in congenital malformations or lethality, and in adults, it results in disturbances in vision and reproduction and metaplasia of epithelial tissues. Vitamin A excess during embryonic development results in malformations in neural tube-derived structures and limb duplications (13) . Because the developmental consequences of retinoid deficiency, as well as toxicity, are severe, the mechanisms that regulate RA levels in tissues are critical.
In vertebrates, the effects of RA are mediated primarily through gene transcription, via several members of the steroid/ thyroid/vitamin D superfamily of nuclear receptors: the retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which each comprise three different subtypes (␣, ␤, and ␥) and which bind RA and 9-cis-RA, respectively, with high affinity. RARs and RXRs have been shown to bind as heterodimers to RA response elements of RA target genes (14) . Genetic and biochemical evidence suggests that the nuclear receptor heterodimers are essential for RAR-mediated RA signaling (15) (16) (17) . Other high-affinity retinoid binding proteins, the retinol binding proteins (CRBP-I and CRPB-II) (18) , and the retinoic acid binding proteins (CRABP-I and CRABP-II) (18) , may be involved in RA synthesis and metabolism; however, their role is unclear (19, 20) .
Although much progress has been made in understanding how RA mediates its biological effects, the functions of RA synthesis and metabolism in RA signaling remain unclear. RA homeostasis is maintained by regulation of its rate of synthesis from retinol (21, 22) and by controlling its rate of degradation through oxidative pathways that give rise to 4-OH-RA and 4-oxo-RA or to 18-OH-RA (23) . The catabolic activities have been studied for many years in microsomal preparations (see, e.g. Ref. 24) , and have been found to have properties characteristic of the cytochrome P450 family, such as dependence on NADPH and oxygen, inhibition by carbon monoxide, and inhibition by the general P450 inhibitors ketoconazole and liarozole (25, 26) .
Recently, we cloned and characterized a RA-inducible cytochrome P450 that specifically metabolizes RA to hydroxylated products, including 4-OH-RA and 4-oxo-RA, and is expressed in the wound epithelium of zibrafish regenerating caudal fin (27) . The human P450RAI counterpart has been identified, and its expression has been studied in a variety of human cell lines (28) . In the breast cancer-derived epithelial cell line MCF-7, metabolic activity and P450RAI mRNA are closely correlated at various times after RA treatment, whereas the nonmalignant, nontransformed breast epithelial cell line MCF-10A has neither P450RAI expression nor RA metabolic activity following RA treatment (28) . These findings strongly implicate P450RAI as a key participant in RA-inducible metabolism, which may act in limiting cellular RA levels.
To address the role of RA metabolism in RA signaling and cell differentiation, we cloned the murine P450RAI counterpart, assessed its metabolic activity by expressing it in COS-1 cells, and studied its expression in the F9 murine embryonal carcinoma cell line, which differentiates into primitive, parietal, or visceral endoderm depending on the RA treatment conditions and is known to have RA-inducible RA metabolic activity (29 -31) . Previous work (32) using F9-derived RAR knockout lines, has implicated RAR␥ and RAR␣ in the regulation of RA metabolism. In our present study, we used F9 wild-type, RAR␣Ϫ/Ϫ, RAR␥Ϫ/Ϫ, RXR␣Ϫ/Ϫ, RXR␣Ϫ/Ϫ/RAR␥Ϫ/Ϫ, and RXR␣Ϫ/Ϫ/RAR␣Ϫ/Ϫ cell lines and a number of receptor-specific synthetic retinoids to establish whether P450RAI was responsible for RA-induced RA metabolism and which receptors were involved in its regulation.
EXPERIMENTAL PROCEDURES
Cloning and Expression of Mouse P450RAI-The mouse homolog of P450RAI was isolated from a RA-induced P19 teratocarcinoma cDNA library in Unizap XR (Stratagene). A total of 10 6 independent plaques were plated and screened using a 32 P-labeled random-primed fulllength human P450RAI probe. Hybridization conditions were as described previously (28) . pBluescript-containing colonies were generated using the in vivo excision protocol (Stratagene) and plated onto LBampicillin plates. DNA was prepared using the Qiaprep Mini-Plasmid kit (Qiagen). Sequencing of the cDNA clone was done using an Applied Biosystems model 373A automated DNA sequencer. For expression in cultured cells, full-length cDNA was cut out of pBluescript using the ApaI and NotI sites and subcloned into pRC/CMV expression plasmid (Invitrogen) cut with the same restriction enzymes.
Cell Culture-All F9 cell lines (wild-type, RAR␣Ϫ/Ϫ (32), RAR␥Ϫ/Ϫ (19), RXR␣Ϫ/Ϫ (33), RXR␣Ϫ/Ϫ/RAR␥Ϫ/Ϫ, 2 and RXR␣Ϫ/Ϫ/RAR␣Ϫ/Ϫ 2 ) were maintained as described previously (29) . In brief, cells were grown in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with glucose (4.5 g/liter), 10% fetal bovine serum, penicillin, streptomycin, fungizone, and gentamycin. For general maintenance, cells were split every other day, seeded into gelatinized tissue culture plates, and incubated in a humidified, 37°C atmosphere of 5% CO 2 . For experiments involving treatment with RA, cells were plated at 1.3 ϫ 10 6 cells per 100-mm tissue culture plate, grown overnight, and treated with all-trans-RA at 1 M in dimethyl sulfoxide or with 0.1% dimethyl sulfoxide only. RA treatments were done under reduced light conditions. For removal of RA from the medium, cells were washed twice with phosphate-buffered saline followed by the addition of fresh medium.
Northern Blot Analysis-Following cell treatment, total RNA was extracted using TRIzol Reagent (Life Technologies, Inc.) as outlined by the manufacturer. Gel electrophoresis and Northern blotting onto nitrocellulose (Hybond C, Amersham Corp.) were performed as described by White et al. (27) using 20 g of total RNA. Radiolabeled mouse P450RAI cDNA probes were prepared by random priming of cDNA using the Stratagene Prime-It kit. Following hybridization in QuickHyb (Stratagene) and membrane washings as described by the manufacturer, blots were exposed to Kodak X-OMAT AR or BIOMAX MR film at Ϫ70°C. To control for quantitation between RNA samples, blots were probed with 32 P-labeled 36B4 cDNA, a ribosomal phosphoprotein, the expression of which is not altered by treatment with RA (32) .
Analysis of RA Metabolic Activity of Mouse P450RAI and HPLC-COS-1 cells were transfected with either mouse P450RAI in expression vector pRC/CMV or empty vector control DNA, along with ferridoxin and ferridoxin reductase expression vectors, as described previously (27, 28) . Extraction of the products from cell culture media and HPLC analysis of the products from COS-1 cells or F9 cells expressing P450RAI treated with unlabeled or 3 H-labeled RA substrates have been previously described (28) . Briefly, media from treated cells incubated with 575 pM all-trans- [11,12- 3 H]RA (23.1 Ci/mmol) for 4 h were acidified to pH 6.1 with glacial acetic acid (0.1%). Lipid-soluble and aqueoussoluble metabolites in the media were separated using a modified Bligh and Dyer total lipid extraction (35) . Conversion of all-trans- [11, H]RA to total aqueous-soluble metabolites was measured by liquid scintillation counting of the aqueous-soluble extract. Lipid-soluble extracts were evaporated to dryness under a stream of nitrogen and resuspended in 93.5:5:1:0.5, hexane/isopropyl alcohol/methanol/acetic acid. Metabolites were separated by HPLC using Zorbax-CN (6 m, 4.6 mm inner diameter ϫ 25 cm) column eluted with a solvent system of 93.5:5:1:0.5, hexane/isopropyl alcohol/methanol/acetic acid at a flow rate of 1 ml/min.
RT-PCR Analysis-RNA preparation, RT-PCR, and Southern blotting were performed as described previously (19, 32, 33) . 2 In brief, RT-PCR was performed under standard conditions using avian myeloblastosis virus reverse transcriptase and Taq polymerase with 2 g of RNA and 50 pmol of each primer. The PCR primers were as follows: 36B4, 5ЈCAGCTCTGGAGAAACTGCTG-3Ј (nucleotides 290 -309) and 5ЈGTGTACTCAGTCTCCACAGA-3Ј (nucleotides 826 -845) (36); mouse P450RAI, 5ЈCTCCTGATTGAGCACTCGTG-3Ј (nucleotides 841-860) and 5ЈGGATCTGCTATCCATTCAGCTC-3Ј (nucleotides 1168 -1189). The amplifications were done for 17 or 19 cycles, aliquots were electrophoresed on a 1.5% agarose gel, and samples were transferred onto Hybond N membranes. The blots were hybridized to the corresponding random primed mouse P450RAI-or 36B4-labeled cDNA probes. Transcript levels were quantified using a BAS 2000 BioImaging analyzer and normalized to corresponding 36B4 mRNA levels. The mRNA levels were expressed relative to the amount present in wild-type cells treated with 1 M all-trans-RA for 96 h.
Synthetic Retinoids-Retinoids selective for RAR␣ (BMS188, 753 (BMS753)) (37), RAR␤ (BMS189, 453 (BMS453)) (38) , RAR␥ (BMS188, 961 (BMS961)) (37) , and all three RXRs (BMS188, 649 (BMS649)) (39) were a gift from Bristol-Myers Squibb, Pharmaceutical Research Institute (Buffalo, NY). Treatments of F9 cells with synthetic retinoids were for 24 h.
RESULTS
Cloning of P450RAI-A cDNA library derived from RAtreated P19 in Unizap XR (Stratagene) was screened with a full-length cDNA probe from human P450RAI according to procedures previously described. Out of 16 clones isolated, 1 cDNA encoding the full open reading frame was obtained and was found to be 93% identical to the human P450RAI and 68% identical to the zibrafish P450RAI at the amino acid level (Fig.  1) . Regions previously identified as having a high degree of homology between human and zibrafish P450RAIs were almost identical between human and mouse cytochromes, with most differences clustered elsewhere in the cDNA. The genomic sequence of both the mouse and human P450RAIs has also been determined, and there is very close homology in location, size, and sequence of the introns and in the proximal promoter. 3 The high degree of homology among these P450RAIs from different species, their catabolic activities, and their location on syntenic chromosomal regions suggests that these genes are homologous. 4 
RA Metabolic Activity of Mouse P450RAI Expressed in COS-1
Cells-To determine whether the mouse P450RAI had similar RA metabolizing activity to its human and zibrafish counterparts, we cloned the full-length mouse P450RAI into the expression vector pRC/CMV, in which transcription is driven by the CMV promoter. COS-1 cells were transfected with the expression vector containing mouse P450RAI or with the empty vector as a control, using methods previously described (28) . RA metabolism in the transfected cells was measured by HPLC analysis of the lipid-soluble components of the media after incubation with either all-trans [11,12- 3 H]RA (575 pM) or unlabeled all-trans RA (1 M). In addition, the aqueous-soluble fraction of the media from cells incubated with 3 H-labeled RA was counted by liquid scintillation. The pattern of metabolism was the same using this cytochrome P450 as with the human and zibrafish P450RAIs (27, 28) . Cells treated with all-trans- [11,12- 3 H]RA and transfected with pRC/CMV-P450RAI ( Fig.  2A) showed a decrease in the amount of RA substrate compared with cells transfected with empty vector and production of metabolites that eluted at 9.5 and 11.5 min, corresponding to the elution positions of 4-OH-RA and 4-oxo-RA standards. In the case of the 3 H-labeled substrate, products were measured by collecting and counting fractions, and the broad peaks observed may also contain other metabolites, such as 18-OH-RA, which has been identified as a metabolic product in microsomes from rat testis incubated with RA (23) . The counts in the aqueous-soluble fraction, which may represent glucuronide conjugates and/or products representing further metabolism of RA, are significantly increased in the mouse P450RAI transfectants compared with control cells (Fig. 2B) . With the unlabeled RA substrate (Fig. 2C) , there was also a decrease in the amount of substrate in cells transfected with mouse P450RAI compared with controls. Three metabolites with spectral properties characteristic of retinoids were observed, co-migrating with 18-OH-, 4-OH-, and 4-oxo-RA standards at 9.3, 9.6, and 11.5 min, respectively. An additional uncharacterized peak, present in the culture medium and lacking the characteristic retinoid UV spectrum, was observed at 10.5 min with both P450RAI-transfected and control samples.
Expression of P450RAI in Wild-type and Mutant F9 Cells-F9 cells have previously been shown to exhibit RAinducible RA metabolism (26, 41, 42) . To determine whether any of the RA metabolic activity in F9 cells could be accounted for by P450RAI expression, we assessed P450RAI mRNA expression in F9 cells treated with RA for various lengths of time.
In these experiments, we used a plating density (1.3 ϫ 10 6 cells/100-mm culture dish) that was found to give optimal expression of P450RAI (data not shown). Levels of P450RAI mRNA were higher in RA-treated cells plated at lower density (0.6 -1.3 ϫ 10 6 cells/100-mm culture dish) at all time points tested than in cells plated at higher density (2.5-5 ϫ 10 6 cells/100-mm culture dish).
To study the role of retinoid receptors in RA induction of P450RAI, we compared expression in wild-type F9 cells with expression in several F9 derivatives in which various RARs, RXRs, or combinations of these receptor genes had been knocked out by homologous recombination. In wild-type F9 cells, a high level of P450RAI expression was seen in cells continuously treated with 10 Ϫ6 M all-trans-RA for 24, 36, and 48 h (Fig. 3A) . There was little apparent difference between the induction profile of P450RAI mRNA in RAR␣Ϫ/Ϫ and in wildtype cells. In contrast, there were markedly decreased levels of P450RAI expression in RAR␥Ϫ/Ϫ and RXR␣Ϫ/Ϫ cell lines at all time points. In the RXR␣Ϫ/Ϫ/RAR␥Ϫ/Ϫ double knockout cell line, there was no detectable expression of P450RAI. Because of the effect of cell plating density on P450RAI expression (see above), we performed this experiment at several different plating densities, with similar results (data not shown). We note that those knockout cell lines that poorly differentiate into primitive endoderm following RA treatment (RAR␥Ϫ/Ϫ, RXR␣Ϫ/Ϫ, and RXR␣Ϫ/Ϫ/RAR␥Ϫ/Ϫ) are also the lines in which P450RAI message and RA metabolism were only weakly induced (19, 33 Fig. 3B demonstrate that RA treatment of wild-type and RAR␣Ϫ/Ϫ cells resulted in a large increase in aqueous-soluble radioactivity compared with DMSO-treated control cells. RAR␥Ϫ/Ϫ and RXR␣Ϫ/Ϫ cell lines also showed an increase in aqueous-soluble radioactivity relative to untreated controls, but the counts were significantly lower than in wild-type and RAR␣Ϫ/Ϫ cells. RA treatment of RXR␣Ϫ/Ϫ/RAR␥Ϫ/Ϫ cells resulted in no increase in aqueous-soluble counts. Although 4-OH-RA, 18-OH-RA, and 4-oxo-RA were detectable with all of the F9 derivatives except for the RXR␣Ϫ/Ϫ/RAR␥Ϫ/Ϫ cell line (data not shown), the levels were much lower than those observed in P450RAI-transfected COS cells (Fig. 2, A and C) . This may reflect more efficient downstream processing of hydroxylated RA in F9 cells. The percentage of total recovered counts in the RA substrate peak after HPLC analysis was also determined for all cell lines. Fig. 3 , A and C, shows that the RA recovered is inversely proportional to the level of P450RAI mRNA expression in all the cell lines tested. Thus, in both wild-type and mutant F9 cells, metabolic activity as measured both by generation of water-soluble products and by disappearance of substrate parallels expression of P450RAI mRNA.
RT-PCR Analysis of P450RAI Expression in
Wild-type and Mutant F9 Cells-RNA from F9 cells was reverse transcribed, and P450RAI mRNA levels were measured by PCR analysis, to corroborate and extend the results obtained by Northern blot analysis and to study the effects of receptor-specific retinoids on P450RAI expression. Results similar to those observed in Northern blot analysis were obtained. The level of P450RAI message in RAR␥Ϫ/Ϫ cell line was less than that observed in wild-type F9 (Fig. 4A and B, lanes 1-4 and 21-24) . In RAR␣Ϫ/Ϫ cells, P450RAI was expressed at a higher level than (A and B) or 1 M unlabeled all-trans-RA (C), according to procedures previously described (27, 28) . Lipid-soluble (A and C) or aqueous-soluble (B) extracts of cell culture media were analyzed by HPLC using a Zorbax-CN column and a solvent system of 93. Readings from three independent experiments were averaged and normalized to 36B4 mRNA levels. P450RAI mRNA levels were expressed relative to the amount present in wild-type cells treated with 1 M RA for 96 h, which was assigned a value of 100. in wild-type cells at all time points measured (Fig. 4, A and B , lanes 1-4 and 17-20) ; this was also seen, though not as clearly, with Northern blot analysis (Fig. 3, lanes 1-6) . The RT-PCR analysis included an additional cell line, RXR␣Ϫ/Ϫ/RAR␣Ϫ/Ϫ, which also clearly exhibited a compromised response to RA as measured by the lower level of induction of P450RAI compared with wild-type.
This experiment also showed that 96 h after RA treatment of F9, P450RAI mRNA levels remained elevated. Because there was a high rate of metabolism in RA-induced F9 cells (Fig. 3C) , this suggested the possibility of RA-independent expression of P450RAI. To test this hypothesis, wild-type F9 cells were exposed to 1 M RA for 24 h, followed by the removal of RA from the medium by washing (Fig. 5) . The expression of P450RAI mRNA remained at a constant level throughout the 96 h following washout, indicating that the continuous presence of RA is not necessary for maintenance of P450RAI mRNA levels in F9 cells.
To gain further insight into the retinoid receptor complement required for efficient P450RAI expression, the F9 wild-type cell line was treated with various RAR or RXR receptor subtypespecific synthetic retinoids in combination or alone: BMS961 (RAR␥ agonist), BMS753 (RAR␣ agonist), BMS649 (RXR panagonist), and BMS453 (RAR␤ agonist) (Fig. 6 ). In agreement with the observed expression of P450RAI mRNA in the various F9 receptor knockout lines (Figs. 3A and 4, A and B) , the RAR␥-specific agonist, BMS961, is an effective inducer of P450RAI at 100 nM (Fig. 6, lane 17) . Furthermore, when coincubated with 1 M of the RXR panagonist, BMS649, a higher level of induction is achieved, comparable to that observed after treatment with 100 nM RA (Fig. 6, lanes 18 -20 and 21) . The RAR␣-specific agonist (BMS753) induced a very low level of P450RAI mRNA, but only at a high concentration (100 nM) when coincubated with 1 M of the RXR panagonist (BMS649) (Fig. 6, lane 8) . The RAR␤-specific agonist (BMS453) was ineffective in inducing P450RAI message, either alone or in combination with the RXR panagonist (BMS649) (Fig. 6, lanes  9 -14) . DISCUSSION We have isolated a cDNA clone that represents the mouse homolog of P450RAI, first described in zibrafish and subsequently in human (27, 28) . The mouse P450RAI closely resembled the zibrafish P450RAI (68% homology at the amino acid level) and was almost identical to the human P450RAI (93% amino acid homology). P450RAI cDNA from all three species, when transfected into COS cells, catalyzes metabolism of RA into hydroxylated derivatives, including 4-OH-and 4-oxo-RA (this work and Refs. 27 and 28). After this report was submitted for publication, two reports appeared describing the cloning of mouse cDNA homologs of P450RAI (43, 44) . At the amino acid level, these are identical to the mouse P450RAI described here. However, the metabolic products described by Fujii et al. (43) differ from those observed with our mouse P450RAI; in that study, 5,8-epoxy all-trans-RA (a compound not observed in previous metabolic studies) is described as an important metabolite, in contrast to our study, which indicated that 4-OH-, 18-OH-, and 4-oxo-RA are the most abundant lipid-soluble products. It is likely that these discrepancies have arisen from technical differences in the extraction and characterization of metabolites.
In agreement with previous studies using F9 and other embryonal carcinoma cell lines (26, 41) , our work demonstrates that RA is rapidly metabolized to more polar metabolites in wild-type F9 cells. F9 derivatives lacking RAR␥ or RXR␣ showed a reduced rate of RA metabolism, whereas F9 cells lacking both RAR␥ and RXR␣ showed no detectable RA metabolism. The rapid induction of P450RAI and its expression in F9 wild-type and mutant cell lines correlate exactly with the observed rates of RA metabolism, suggesting that P450RAI may be responsible for most of the RA metabolism observed in F9 cells. Although we did not observe a significant difference in RA metabolism between the wild-type and RAR␣Ϫ/Ϫ cell lines, we note that it has been previously reported that at earlier time points following RA exposure, RA metabolic activity in RAR␣Ϫ/Ϫ cells is greater than that observed in wild-type cells (19) . In the same study, Boylan et al. (19) also demonstrated that RAR␥Ϫ/Ϫ cells have a decreased rate of RA metabolism, which is in agreement with our results. The correlation that we observed between RA metabolism and P450RAI expression does not preclude the possibility that other enzymes are involved in the observed RA metabolism. RA-inducible retinol metabolism has been reported in F9 cells (45, 46) , and because P450RAI does not metabolize retinol in transfected-COS cells (28) , a different enzyme may be involved in retinol metabolism. The enzyme responsible for this activity has not been identified, but it may also have the ability to metabolize RA.
We have observed (Fig. 5 ) that following removal of RA from the medium, F9 cells are capable of RA-independent expression of P450RAI. This sustained level of P450RAI expression in F9 cells following withdrawal of RA could explain the high level of RA metabolism observed when cells pretreated with RA are exposed to a second dose of RA. Such observations have been made in F9 cells by Williams and Napoli (26) , who found that the half-life (3.5 h) of RA in F9 cells is reduced 1.5-fold when cells pretreated with RA are re-exposed to RA. Similarly, it has been observed that in vitamin A deficient hamsters, orally administered RA is slowly metabolized, whereas in animals pre-fed RA, metabolism of subsequently administered RA was much more extensive (47) .
Our results from Northern analysis and RT-PCR analysis of knockout lines suggest that RAR␥ and RXR␣ may be important in mediating the induction of P450RAI. These observations were substantiated using several receptor subtype-specific synthetic retinoids. The RAR␥-specific ligand strongly induced P450RAI, whereas the RAR␣ and RAR␤-specific ligands did not induce detectable P450RAI mRNA expression. The activity of the RAR␥ agonist was further enhanced by the addition of a RXR panagonist, almost to the level of P450RAI-induced expression in wild-type by RA. This is consistent with the view that in most instances, RAR-RXR heterodimers are the functional units, transducing the effects of retinoids both in vivo and in vitro (14 -17, 48) . 2 A clear understanding of RA metabolic activity is critical when considering the activities of retinoids in different cell types or tissues. For example, it may be very important when considering the use of retinoids in the treatment of disease. RA has been found to induce a complete but temporary remission in acute promyelocytic leukemia (10) . Further treatment with RA at relapse is ineffective. This resistance to RA has been attributed to induced RA metabolism by a cytochrome P450 (49) , which could be P450RAI. Because our studies with synthetic retinoids show that P450RAI induction is mediated in a receptor subtype-specific manner, the specificity of synthetic retinoids may be crucial in determining whether or not the RA metabolic pathway is induced. It is possible that some retinoids that either fail to induce RA metabolism or are not substrates for the metabolic pathway may be more effective than alltrans-RA as therapeutic agents in cancer and other diseases (34, 40, 50 -52) . In addition, RA is known to play a crucial role in development, and P450RAI, which is known to be expressed in a precise spatiotemporal pattern during development (43), 5 may provide a mechanism for tight control of RA at the tissue level. An important test of both this notion and our hypothesis on the involvement of P450RAI in RA metabolism will be the ablation of the P450RAI gene from F9 cell lines and the mouse genome.
